Pharmena S.A. Logo

Pharmena S.A.

Develops dietary supplements using its patented 1-MNA molecule to support healthy aging.

PHR | WAR

Overview

Corporate Details

ISIN(s):
PLPHRMN00011
LEI:
259400RHT936BBKW0955
Country:
Poland
Address:
ŁÓDŹ GDAŃSKA 47/49, 90-729 ŁÓDŹ
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Pharmena S.A. is a biotechnology company specializing in the development and commercialization of innovative products based on its patented, proprietary 1-MNA molecule. This naturally occurring substance, a metabolite of vitamin B3, is foundational to the company's offerings, which aim to support healthy aging by regulating cellular metabolism. Following the strategic divestment of its dermo-cosmetics division, Pharmena now concentrates on the dietary supplements market, including its flagship Endotelio brand. The company is also expanding its research and development into new areas, such as advanced medical devices for wound care.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-08 13:56
Regulatory News Service
Zawarcie umowy na wykonanie badań biokompatybilności przyszłego wyrobu medyczne…
Polish 1.6 KB
2025-07-16 10:53
Regulatory News Service
Rozpoczęcie współpracy z Shop Apotheke w zakresie sprzedaży suplementów diety w…
Polish 1.2 KB
2025-07-07 10:12
Regulatory News Service
Zawarcie umowy na opracowanie dokumentacji oraz wytworzenie serii walidacyjnych…
Polish 2.0 KB
2025-06-25 16:52
Declaration of Voting Results & Voting Rights Announcements
PHR_Wykaz akcjonariuszy posiad. pow. 5% głosów na ZWZ w dniu 25 06 2025
Polish 50.1 KB
2025-06-25 16:52
Major Shareholding Notification
Wykaz akcjonariuszy posiadających co najmniej 5% liczby głosów na ZWZ w dniu 25…
Polish 525 bytes
2025-06-25 16:51
Board/Management Information
250625_Informacja dot Jacka Szwajcowskiego
Polish 306.7 KB
2025-06-25 16:51
Board/Management Information
250625_Informacja dot Zbigniewa Molenda
Polish 224.2 KB
2025-06-25 16:51
Board/Management Information
250625_Informacja dot. Anny Paczkowskiej
Polish 239.0 KB
2025-06-25 16:51
Board/Management Information
250625_Informacja dot Tomasz Filipiak
Polish 192.5 KB
2025-06-25 16:51
Board/Management Information
250625_Informacja dot Agnieszki Dziki
Polish 146.7 KB
2025-06-25 16:51
Board/Management Information
250625_Informacja dot Jacka Dauenhauera
Polish 225.0 KB
2025-06-25 16:51
Post-Annual General Meeting Information
Powołanie członków Rady Nadzorczej na nową kadencję - Content (PL)
Polish 1.3 KB
2025-06-25 16:50
Post-Annual General Meeting Information
Treść uchwał podjętych przez ZWZ PHARMENA S.A. w dniu 25 06 2025
Polish 176.8 KB
2025-06-25 16:50
Post-Annual General Meeting Information
Treść uchwał podjętych przez ZWZ PHARMENA S.A. w dniu 25.06.2025 r. - Content (…
Polish 822 bytes
2025-05-29 14:57
Board/Management Information
zal03_Oswiadczenie_Jacek_Szwajcowski.pdf
Polish 646.9 KB

Automate Your Workflow. Get a real-time feed of all Pharmena S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Pharmena S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
ONCODESIGN Logo
Developing precision oncology solutions for resistant and metastatic cancers.
France ALONC
Oncodesign Precision Medicine S.A Logo
Develops precision therapies & diagnostics for resistant and metastatic cancers.
France ALOPM
Oncoinvent ASA Logo
Developing alpha-emitting radiotherapies for treating cancers in the peritoneal cavity.
Norway OCIN
Oncolys BioPharma Inc. Logo
Developing oncolytic virus therapies and diagnostics for cancer and serious viral infections.
Japan 4588
Oncopeptides Logo
Develops targeted therapies for hematological cancers using peptide-drug conjugate technology.
Sweden ONCO
Onesano S.A. Logo
Develops patented nutritional products for humans, animals, and agriculture.
Poland SKT
ONO PHARMACEUTICAL CO., LTD. Logo
Develops innovative medicines for high unmet needs in oncology, immunology, and neurology.
Japan 4528
OPKO Health Inc. Logo
Provides clinical diagnostics & develops novel therapies for serious & pediatric diseases.
Israel OPK
OPTUS Pharmaceutical Co., Ltd. Logo
Develops and manufactures ophthalmic solutions for dry eye, infections, and inflammation.
South Korea 131030
Oramed Pharmaceuticals Inc. Logo
Develops oral drug delivery systems to turn injectable drugs, like insulin, into oral therapies.
Israel ORMP

Talk to a Data Expert

Have a question? We'll get back to you promptly.